TORONTO, ONTARIO -- (Marketwire) -- 03/19/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) has appointed Dr. Guillermo A. Duran as Chief Medical Officer. Dr. Duran discovered Follicle Nutrient Deficiency Syndrome (FNDS) to be the causal effect of alopecia and went on to develop the preventive and regenerative treatment now known as the Biologix Hair Therapy System.
Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients by a select private consortium of medical clinicians located in South America. Participating patients either suffered with varying degrees of FNDS or were seeking preventive treatment to avoid onset of FNDS.
During those eight years, the clinicians subjectively estimated that healthy hair growth has been maintained in virtually 100% of those whose goal was to prevent the onset of Follicle Nutrient Deficiency Syndrome (FNDS) and resulting alopecia.
The clinicians further estimate that between 80 - 85% of their male patients and upwards of 90% of their female patients being treated for FNDS and seeking hair regeneration therapy have been able to regrow their lost hair.
Of the alopecia areata patients - both men and women - the rate of success has been observed to be nearly 100%.
Dr. Guillermo Duran is a medical doctor practicing in Barranquilla, Colombia. He graduated in 1988 from Juan N. Corpas University's medical school in Bogota and completed specialization in mesotherapy in 2000 at the Universite Victor Segalen Bordeaux 2 in France. Between 1994 and 2012 Dr. Duran continued his study of mesotherapy and esthetic medicine in Brazil.
From 1989 to 1990 Dr. Duran served as Executive Director of San Roque Hospital, as an Intensive Care Unit physician at the Ramon Gonzalez Valencia Hospital in Bucaramanga from 1991-92. He has been in private practice in mesotherapy and esthetic medicine since 1993. Dr. Guillermo Duran has been a guest speaker on the topic of trichology at several conferences, including in Brazil in 2008, Spain in 2011, and three times in Colombia from 2008-10.
Ron Holland, CEO of Biologix Hair Inc., commented, "I commend Dr. Guillermo Duran for his professionalism and high scientific and research standards. His discovery of FNDS and resultant formulation of what has become Biologix Revive promises to be a significant contribution to science and a benefit to millions of people around the world, if and when regulatory approval is granted. As we continue to take the necessary steps to prepare for application for regulatory agency approval, Dr. Duran's direct assistance as Chief Medical Officer will be especially helpful during this process."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- TFA Recruiting DACA Recipients
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Tea Party Glum in Face of Bipartisan Budget Deal
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Health Coverage Disparities Emerge Among States